When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study.
BACKGROUND For clinicians , confidence in atrial fibrillation ( AF ) episode classification is an important consideration when electing to use insertable cardiac monitors ( ICMs ) . OBJECTIVE The purpose of this study was to report on the improved AF detection algorithm in the Reveal LINQ ICM . METHODS The Reveal LINQ Usability Study is a nonr and omized , prospect i ve , multicenter trial . The ICM has been miniaturized , uses wireless telemetry for remote patient monitoring , and its AF algorithm includes a new p-wave filter . At 1 month post-device insertion , Holter monitor data were collected and annotated for true AF episodes ≥2 minutes , and performance metrics were evaluated by comparing Holter annotations with ICM detections . RESULTS The study enrolled 151 patients ( age 56.6 ± 12.1 , male 67 % ) . Reasons for monitoring included  AF ablation or AF management in 81.5 % ( n = 123 ) , syncope in 12.6 % ( n = 19 ) , and other indications in 5.9 % ( n = 9 ) of patients . Of the 138 patients with an analyzable Holter recording , a total of 112 true AF episodes were identified in 38 patients ( 27.5 % ) . The overall accuracy of the ICM to detect duration s of AF or non-AF episodes was 99.4 % , and the AF burden measured by the ICM was highly correlated with the Holter ( Pearson coefficient 0.995 ) . CONCLUSION The new AF detection algorithm in the Reveal LINQ ICM accurately detects the presence or absence of AF . Additionally , it showed high sensitivity in detecting AF duration in patients with a history of intermittent and symptomatic AF
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .